Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 January 2023Website:
http://www.cadrenal.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 15 Nov 2024 21:38:19 GMTDividend
Analysts recommendations
Institutional Ownership
CVKD Latest News
Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit PONTE VEDRA, Fla. , Nov. 12, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, today highlighted a key opinion leader presentation at the November 2024 European Association for Cardio-thoracic Surgery (EACTS) Mechanical Circulatory Support Summit that featured tecarfarin historical data and Cadrenal's proposed clinical trial protocol to evaluate tecarfarin versus warfarin in patients with the Abbott HeartMate3 (HM3) left ventricular assist device (LVAD).
PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 285,715 shares of common stock of the originally issued in July 2023, having an exercise price of $26.25 per share, at a reduced exercise price of $16.50 per share.
Participation Reinforces Cadrenal's Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy PONTE VEDRA, Fla. , Oct. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to improve anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today announced its membership in the Corporate Council of the Anticoagulation Forum (AC Forum).
PONTE VEDRA, Fla. , Aug. 22, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, announced today that it will be engaging with the U.S. Food and Drug Administration (FDA) in early September for a Type-B meeting to discuss its clinical trial for tecarfarin in LVAD patients.
Analysis features the growing need to evolve anticoagulation therapy beyond warfarin to avoid gastrointestinal bleeding, a significant and common complication for left ventricular assist device (LVAD) patients resulting in expensive hospitalizations Tecarfarin, a novel vitamin K antagonist (VKA), uses a different metabolic pathway than warfarin, the most commonly used anticoagulant for LVAD patients, and may offer more stable and effective anticoagulation PONTE VEDRA, Fla. , Aug. 20, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation VKA oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices or rare cardiovascular conditions, today highlighted a manuscript that was recently peer-reviewed and published in the Journal of Cardiac Failure evaluating the relationship between time in therapeutic range, or TTR, management quality and LVAD patient clinical outcomes.
PONTE VEDRA, Fla. , Aug. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, today provided a corporate update coinciding with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.
PONTE VEDRA, Fla. , June 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today announced that the Company will be participating in the Emerging Growth Conference on June 12, 2024.
Cadrenal Therapeutics (NASDAQ: CVKD ) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. There have been no new press releases from Cadrenal Therapeutics that explain why its stock is up today.
It has been a tough, quiet year in the market for initial public stock offerings (IPOs) which has investors eagerly searching for high potential IPOs. In the global IPO landscape, the first quarter of 2023 witnessed a total of 299 IPOs, raising an amount of $21.5 billion.
What type of business is Cadrenal Therapeutics Common Stock?
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
What sector is Cadrenal Therapeutics Common Stock in?
Cadrenal Therapeutics Common Stock is in the Healthcare sector
What industry is Cadrenal Therapeutics Common Stock in?
Cadrenal Therapeutics Common Stock is in the Biotechnology industry
What country is Cadrenal Therapeutics Common Stock from?
Cadrenal Therapeutics Common Stock is headquartered in United States
When did Cadrenal Therapeutics Common Stock go public?
Cadrenal Therapeutics Common Stock initial public offering (IPO) was on 20 January 2023
What is Cadrenal Therapeutics Common Stock website?
https://www.cadrenal.com
Is Cadrenal Therapeutics Common Stock in the S&P 500?
No, Cadrenal Therapeutics Common Stock is not included in the S&P 500 index
Is Cadrenal Therapeutics Common Stock in the NASDAQ 100?
No, Cadrenal Therapeutics Common Stock is not included in the NASDAQ 100 index
Is Cadrenal Therapeutics Common Stock in the Dow Jones?
No, Cadrenal Therapeutics Common Stock is not included in the Dow Jones index
When was Cadrenal Therapeutics Common Stock the previous earnings report?
No data
When does Cadrenal Therapeutics Common Stock earnings report?
Next earnings report date is not announced yet